Total and commonly reported (⩾5%) treatment-emergent adverse events
| Adverse event | Sulfasalazine (n = 50) | Etanercept (n = 103) | Etanercept and sulfasalazine (n = 101) |
|---|---|---|---|
| Values are % (n). | |||
| *p<0.05, sulfasalazine versus etanercept. | |||
| †p<0.05, sulfasalazine versus combination. | |||
| ‡p<0.05, etanercept versus combination. | |||
| §Includes cold sore, folliculitis, herpes simplex, localised fungal infections, phlebitis, pityriasis versicolor and ulcerative lesion. | |||
| Non-infectious adverse events | |||
| Total | 58.0 (29) | 71.8 (74) | 71.3 (72) |
| Injection site reaction | 2.0 (1) | 32.0 (33)* | 15.8 (16)†‡ |
| Headache | 8.0 (4) | 4.9 (5) | 14.9 (15)‡ |
| Nausea | 6.0 (3) | 2.9 (3) | 11.9 (12)‡ |
| Asthenia | 2.0 (1) | 2.9 (3) | 9.9 (10)‡ |
| Rash | 4.0 (2) | 9.7 (10) | 7.9 (8) |
| Cough increased | 8.0 (4) | 2.9 (3) | 5.9 (6) |
| Arthralgia | 8.0 (4) | 2.9 (3) | 5.0 (5) |
| Rhinitis | 8 (4.0) | 1.0 (1) | 2.0 (2) |
| Abdominal pain | 0 | 6.8 (7) | 7.9 (8) |
| Bronchitis | 2.0 (1) | 7.8 (8) | 4.0 (4) |
| Pruritus | 4.0 (2) | 1.0 (1) | 6.9 (7) |
| Injection site haemorrhage | 6.0 (3) | 4.9 (5) | 5.0 (5) |
| Pharyngitis | 6.0 (3) | 4.9 (5) | 4.0 (4) |
| Pain | 6.0 (3) | 3.9 (4) | 2.0 (2) |
| Fever | 6.0 (3) | 0* | 2.0 (2) |
| Dyspepsia | 2.0 (1) | 5 (4.9) | 5.9 (6) |
| Dizziness | 2.0 (1) | 3.9 (4) | 5.9 (6) |
| Accidental injury | 0 | 5.8 (6) | 3.0 (3) |
| Hypertension | 0 | 2.9 (3) | 5.9 (6) |
| Leucopenia | 0 | 1.0 (1) | 5.0 (5) |
| Paraesthesia | 2.0 (1) | 1.9 (2) | 5.9 (6) |
| Infectious adverse events | |||
| Total | 26.0 (13) | 45.6 (47)* | 30.7 (31)‡ |
| Pharyngitis or laryngitis | 6.0 (3) | 11.7 (12) | 5.0 (5) |
| Upper respiratory infection | 10.0 (5) | 9.7 (10) | 10.9 (11) |
| Flu syndrome | 2.0 (1) | 7.8 (8) | 5.0 (5) |
| Miscellaneous skin infections§ | 2.0 (1) | 8.7 (9) | 5.5 (5) |